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Abstract 
Yellow fever virus (YFV), a member of the Flaviviridae family, is an arthropod-borne 
virus that can cause severe disease in humans with a lethality rate of up to 60%. 
Since 2017, increases in YFV activity in areas of South America and Africa have 
been described. Although a vaccine is available, named strain 17D (Theiler and 
Smith, 1937), it is contraindicated for use in the elderly, expectant mothers, 
immunocompromised people, among others. To this day there is no antiviral 
treatment against YFV to reduce the severity of viral infection. Here, we used a 
circular polymerase extension reaction (CPER)-based reverse genetics approach to 
generate a full-length reporter virus (YFVhb) by introducing a small HiBit tag in the 
NS1 protein. The reporter virus replicates at a similar rate to the parental YFV in 
HuH-7 cells. Using YFVhb, we designed a high throughput antiviral screening 
luciferase-based assay to identify inhibitors that target any step of the viral 
replication cycle. We validated our assay by using a range of inhibitors including 
drugs, immune sera and neutralizing single chain variable fragments (scFv). In light 
of the recent upsurge in YFV and a potential spread of the virus, this assay is a 
further tool in the development of antiviral therapy against YFV.  
 
 
Keywords: yellow fever virus, HiBiT, luciferase, drug screen, CPER 
 
Abbreviations: yellow fever virus (YFV), single chain variable fragments (scFv), 
plaque reduction neutralization test (PRNT), circular polymerase extension reaction 
(CPER), NanoLuc binary technology (NanoBiT), large NanoBiT subunit (LgBiT), 
Mycophenolic acid (MPA), hepatitis delta virus ribozyme (HDVr), SV40 
polyadenylation signal (pA), soluble E protein (sE), test bleed (TB) 
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1. Introduction 
Yellow fever virus (YFV), a Flaviviridae family member, is an arthropod borne 
virus mainly transmitted to vertebrate hosts by mosquitoes of the Aedes and 
Haemagogus species (Huang, 1986; Monath, 1994; Mutebi and Barrett, 2002; 
Vasconcelos et al., 2003). In recent years, YFV has remerged in Africa and South 
America as exemplified by the current worst YFV outbreak in Brazil in years 
(Goldani, 2017; Jácome et al., 2019; Otshudiema et al., 2017; Possas et al., 2018). 
Although a vaccine against YFV exists, limitations with the vaccine formulation, 
severe adverse effects, and shortage of supply have boosted the interest in equally 
effective yet safer vaccine strategies (Julander et al., 2018; Monath et al., 2010; Pato 
et al., 2019; Tottey et al., 2018). Moreover, there is no therapeutic treatment to 
reduce the severity of YFV infections and patients rely on palliative care. Importantly, 
the lethality of YFV has been reported to be as high as 60% (Monath, 2008). 
Rapid and sensitive assays that are amenable to high-throughput screening are 
required to identify and assess the efficacy of antiviral therapeutics. The classical 
way to measure viral neutralization by antibodies is through the plaque reduction 
neutralization test (PRNT) (Spector and Tauraso, 1968), however, this technique is 
laborious, time consuming and low-throughput. Replicons of YFV encoding reporter 
genes have been previously developed (Jones et al., 2005; Queiroz et al., 2013) and 
used to screen viral inhibitors (Patkar et al., 2009). However, replicons only encode 
non-structural genes, thus, identification of YFV inhibitors is limited to replication-
associated targets, ignoring entry/exit pathways and spread. Importantly, this method 
cannot screen neutralising agents (antibodies/antivirals) against the envelope (E) 
protein, which is the target of most neutralising antibodies (Vratskikh et al., 2013) 
and some drugs (Mayhoub et al., 2011). Thus, reporter viruses are better candidates 
to identify a broader range of inhibitors targeting the virus. 
Reporter viruses also have been widely used for the development of high-throughput 
neutralization assays (Deng et al., 2016; Gadea et al., 2016; Schoggins et al., 2012; 
Song et al., 2014; Zhang et al., 2016). Nevertheless, the length and size of the most 
common reporters can interfere with virus replication and result in significant virus 
attenuation. Although tags have been successfully added in the capsid region, the 
NS1 gene has been shown to be more tolerable to insertions, which often resulted in 
a more stable reporter virus (Eyre et al., 2017). An optimal tag should thus minimise 
dimensional intrusion and provide a quantifiable range of protein expression that is 
proportional to virus replication. Here we describe the development of a YFV vaccine 
strain 17D-based reverse genetics system to produce a virus carrying an 11-amino 
acid-long, HiBiT tag based on in vitro bacterium free approach adapted from Setoh 
et al. (2017). The HiBiT is a component of the NanoLuc binary technology 
(NanoBiT), but it lacks the enzymatic activity on its own. This activity is restored 
upon the association of HiBiT with large NanoBiT subunit (LgBiT), which generates 
an enzyme capable of bioluminescence (Schwinn et al., 2018). The reporter virus 
(YFVhb) displayed similar growth kinetics and titres in HuH-7 cells to the parental 
vaccine strain virus. Furthermore, the reporter virus can be used to develop a highly 
sensitive high-throughput antiviral screening assay (Z values 0.69, signal-to-
background ratio >1000). Indeed we were able identify to new inhibitors of YFV, 7-
deaza-2'-C-methyladenosine (7DMA), Celgosivir and Nelfinavir. 
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2. Methods and Materials 
2.1. Cell lines and virus 
BHK-21, HuH-7, Vero, and A549-NPro were maintained in Dulbecco’s Modified 
Eagle Medium (Life Technologies) supplemented with 10% fetal bovine serum (FBS) 
(Life Technologies), 1% non-essential amino acids, penicillin (100 IU/ml) 
streptomycin (0.1 mg/ml) (Gibco), and 10mM HEPES buffer (Gibco). Cells were 
cultured at 37°C, in 5% CO2 under a humidified atmosphere. S2 drosophila cells 
were maintained in Schneider’s complete medium (Gibco) supplemented with 10% 
FBS, and Penicillin (100 IU/ml) Streptomycin (0.1 mg/ml) at 28°C. Expi293F cells 
(Thermo Fisher Scientific) were grown in Expi293TM Expression Medium following 
manufacturer’s instructions. The A549-NPro (puromycin resistant) cells expressing 
IRF3-degrading BVDV NPro were a kind gift from R.E Randall (University of St. 
Andrews, UK) and maintained in the presence of 2µg/ml puromycin (Hilton et al., 
2006). YFV vaccine strain 17D (catalogue number 0006251v) was acquired from 
Public Health England (PHE). The parental YFV vaccine strain 17D (YFV-17D) 
infectious clone used in this study is a derivative of the infectious clone 
pACNR/FLYF-17Dx (Bredenbeek et al., 2003). The derivative, designated pACNR-
2015FLYF-17Da, was created using standard molecular biology techniques and 
differs from pACNR/FLYF-17Dx by a) the presence of an AflII site for DNA 
linearization prior to in vitro RNA production, b) a C nucleotide (nt) at YFV-17D 
position 8212, which had originally been mutated to a T (CTCGAG changed to 
CTTGAG) to allow the use of XhoI as the linearization run-off site, and c) a G at nt 
4025, rather than an A, since upon comparison of multiple vaccine strain sequences 
available in Genbank (including deposited sequences for 17DD, 17D-204 and 17D-
213), as well as to published 17D-204 deep sequencing data (Beck et al., 2014) this 
is uniformly a G. Plasmid pACNR-2015FLYF-17Da was verified by complete 
sequencing and the sequence has been deposited to Genbank (accession number: 
MT114401). 
2.2. Reagents 
Mycophenolic acid (MPA) was purchased commercially (Merck), and dissolved in 
methanol or DMSO. 7DMA (Biosynth carbosynth), Sinefungin (Abcam), Ribavirin 
(Merck), Ivermectin (Merck), ARDP0006 (Merck), Celgosivir (Merck), and Nelfinavir 
(Merck) were dissolved in DMSO. Pan-flavivirus monoclonal antibody 4G2 (Henchal 
et al., 1982) was purified from a hybridoma line D1-4G2-4-15 obtained from ATCC 
(HB-112). Donkey anti-mouse IgG (H+L) Alexa Fluor 488 (A-21202) and Invitrogen-
V5 tag Monoclonal antibody (R960-25) were acquired from Thermo Fisher Scientific 
and goat anti-mouse IgG peroxidase antibody (A4416) from Merck. IRDye 680RD 
Donkey anti-mouse IgG secondary antibody (926-68072) was obtained from LI-COR 
Biosciences. 
2.3. Generation of recombinant reporter virus by CPER 
The reporter virus was generated by an adapted CPER method as described 
previously for ZIKV (Setoh et al., 2017). Seven overlapping fragments covering the 
entire YFV genome were amplified with the respective primers (Table 1) and KOD 
DNA polymerase (Merck) from YFV-17D infectious clone pACNR-2015FLYF-17Da 
(Supplementary Sequence S1). An additional overlapping nucleotide fragment 
containing the HiBiT tag was synthesised and amplified (Supplementary Sequence 
S2). The overlapping fragments plus the linker fragment, which contains a CMV-
promoter, a hepatitis delta virus ribozyme (HDVr), and an SV40 polyadenylation 
signal (pA) were mixed in equimolar amounts (0.1 pmol) and subjected to CPER with 
Phusion DNA polymerase (2 minutes of denaturation at 98°C; 20 cycles of 10 
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seconds at 98°C, 15 seconds at 64°C, and 12 minutes at 72°C; and a final extension 
for 12 minutes at 72°C) to circularise the DNA. The crude CPER product mixture was 
directly transfected into BHK-21 cells using Lipofectamine 2000 (Thermo Fisher 
Scientific). Infection was allowed to progress for a week before harvesting the media. 
To amplify the virus, HuH-7 were infected at a multiplicity of infection (MOI) 0.01 for 
72 hours. 
2.4. Infection with YFV-17D or YFVhb  
Different mammalian cell lines were infected with either YFVhb or YFV-17D (from 
PHE) at a MOI 0.01 for 1 hour. After virus absorption, the inoculum was removed; 
cells were washed with PBS and incubated for 72-96 hours with DMEM 
supplemented with 2% FBS, 1% non-essential amino acids, penicillin (100 IU/ml) 
streptomycin (0.1 mg/ml), 10µM HEPES buffer. Then, virus in the cell supernatant 
was titrated in a 50% tissue culture infective dose (TCID50) assay. For replication 
kinetics assays with YFVhb, Vero, BHK-21, HuH-7, and A549-NPro were seeded at 
a density of 2x104 cells per well in a 96-well plate format overnight. The next day, 
plates were placed on ice for 30 minutes before infecting the cells with YFVhb at a 
MOI of 1 for 1 hour on ice to synchronise the infection. Plates were then washed with 
PBS to remove any unbound virus, and 100 µl of DMEM (2% FBS) was added to the 
cells. Plates were incubated at 37°C, 5% CO2 under a humidified atmosphere and 
Nano-Glo HiBiT Lytic Detection System (Promega) was used to measure 
luminescence on GloMax microplate reader (Promega). 
2.5. Titration of virus by TCID50 
HuH-7 cells were infected with 10-fold serial dilutions in heptuplicate in a 96 well 
plate for 72 hours at 37°C in 5% CO2. After incubation, the supernatant was 
discarded, and cells were fixed in 100% methanol at -20°C for 2 hours. Plates were 
washed with PBS-0.05% Tween-20 and fixed cells were incubated with pan-flavivirus 
MAb 4G2 at 3 µg/ml for 1 hour, which binds to the virus envelope (E) protein 
(Henchal et al., 1982). Bound antibodies were detected using goat anti-mouse IgG 
(H+L)-Alexa Fluor 488 at a dilution of 1:500. The TCID50 was calculated using the 
Spearman-Kärber algorithm (Hierholzer and Killington, 1996). 
2.6. YFVhb inhibitor and antiviral assay 
HuH-7 cells were seeded at a density of 2x104 cells/well in a 96-well plate. The 
following day, cells were infected with YFVhb at MOI 0.01. To test drugs against 
YFVhb or YFV, cells were pre-incubated with the drug for 1 hour prior to infection 
with the virus and the drug was present during the 48 hour course of the experiment. 
For antibody-mediated neutralization, 4X102 YFVhb infectious units were pre-treated 
with serial dilutions of scFv-5A or mouse sera for 1 hour at 37°C and then cells were 
incubated with the mixture for 48 hours. scFv-5A (Accession number AY661701.1) 
was expressed in drosophila S2 cells and purified as described by Backovic et al. 
(2010) and Backovic and Krey (2016). Nanoluciferase signal was detected using 
Nano-Glo HiBiT Lytic Detection System (Promega) utilising a GloMax microplate 
reader. Cytotoxicity of the panel of drugs was assessed by incubation of the cells 
with drug under screening conditions, only without virus. Cell proliferation reagent 
WST-1 (Roche) was used to measure cell viability at different drug concentrations. 
The data was normalised to the values obtained from incubation with the drug 
vehicle, DMSO.  
2.7. Z-factor  
For Z-factor determination, 40 replicates of a positive control (MPA 10 µM) and 40 
replicates of a negative control (MPA vehicle, methanol) were compared using the 
YFVhb assay described in this study. Briefly, HuH-7 cells were pre-incubated for 1 
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hour with either 10 µM of MPA or compound vehicle (methanol) at appropriate 
dilutions. Then, without removing the compound or methanol, YFVhb was added at a 
MOI 0.01 and incubated for 48 hours. The Z-factor was calculated according to the 
formula previously proposed by Zhang et al. (1999). 
2.8. Generation of YFV soluble E and immunisation for sera generation 
A mammalian codon optimised YFV soluble E protein (sE) lacking the stem region 
and transmembrane domain (amino acids 394-493) was synthesised. The construct 
was linked to a N-terminal immunoglobulin leader sequence, a C-terminal V5 tag 
(GKPIPNPLLGLD) and Strep tag II. The construct was cloned into a pVAX (a kind 
gift of Dr. Oscar Burrone) vector and transfected using ExpiFectamineTM 293 
Transfection kit (Thermo Fisher Scientific). The protein was purified with Streptrap 
HP column (GE Healthcare) using the ÄKTA Pure (GE Healthcare) system. The 
concentration of sE protein was determined using NanoDropOne (ThermoScientific). 
To generate anti-YFV sera, Balb/c mice (n=6) were subcutaneously immunised with 
5 µg of purified YFV sE protein in 60 µl together with 73 µl of aluminium hydroxide-
monophosphoryl lipid A as an adjuvant. Mice received two identical boosts of YFV 
sE at 14 days intervals. Test bleeds were recovered from mice 2 weeks after each 
boost. Binding of antibodies to YFV E were determined by incubation of serial 
dilutions of mouse sera to biotinylated YFV E protein in an ELISA format. A goat anti-
mouse IgG-peroxidase (Merck) was used as a secondary antibody and TMB as a 
substrate (Life Technologies). 
2.9 Western blot protocol 
Eluted fractions obtained from purification of the sE protein were separated by 10% 
SDS-PAGE under reducing conditions for 1.5 hours at 100V. The proteins were 
transferred to a PVDF membrane by a semi-dry transfer 24V for 30 minutes. The 
PVDF membrane was blocked using Odyssey Blocking Buffer PBS overnight. As a 
primary antibody, Invitrogen-V5 tag Monoclonal antibody was added at a dilution of 
1:1000 for 1-2 hours in blocking buffer. The membrane was washed thrice with 
PBST before addition of the secondary IRDye 680RD Donkey anti-mouse IgG 
secondary antibody (LI-COR). The membrane was washed again and digitally 
developed with LI-COR Image Studio. 
2.10. Plaque assay-based neutralization assay (PRNT) 
Vero cells were seeded at a density of 4x105 cells per well in a 12 well plate. The 
following day, the cells were infected with 80 YFV-17D infectious units previously 
incubated for 1 hour with serial dilutions of mouse sera. Infection was allowed for two 
hours in 2x DMEM 4%FBS before the addition of overlay medium to reach a final 
concentration of 3% carboxymethyl cellulose and 1x DMEM. The cells were then 
incubated for 6-7 days. To develop the plate, cells were gently washed with PBS and 
fixed with 3.7% formaldehyde in PBS for 10 minutes, followed by staining with 0.1% 
crystal violet in 20% ethanol.  
 
3. Results 
3.1. Construction of recombinant reporter virus. 
The reporter virus was constructed by the introduction of the small 11-amino acid 
Nano-Glo HiBiT tag (Schwinn et al., 2018) at the beginning of the non-structural 
protein 1 gene (NS1), one of the areas shown to best tolerate insertions (Bonaldo et 
al., 2007; Eyre et al., 2017; Kassar et al., 2017; Tamura et al., 2017). The HiBiT tag 
was flanked in the N terminus by the first four amino acids of NS1, although encoded 
by a different codon from the original NS1 to maintain the cleavage site and to avoid 
recombination that could excise the tag sequence during viral replication (Fig. 1A). 
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Additionally, at the end of the tag, a protein linker GSSG (4GS) was added to 
improve solubility and flexibility (Chen et al., 2013b). 
To generate the reporter virus YFVhb, we followed the reverse genetics system 
designed previously (Edmonds et al., 2012; Setoh et al., 2017) named CPER. As 
shown in Fig. 1B, seven overlapping fragments were amplified from YFV-17D 
infectious clone pACNR-2015FLYF-17Da. The fragment containing the tag (* in Fig. 
1B) was amplified from a synthetic DNA fragment. Altogether these fragments 
covered the entire reporter virus genome. An additional fragment that contained the 
CMV promoter (for transcription of RNA), HDVr (to ensure correct 3’ terminal 
cleavage of RNA), and SV40 pA was included as well (Fig. 1B); these fragments 
were mixed in equimolar amounts and were subjected to CPER. The CPER products 
were then transfected into BHK-21 cells and the virus produced (YFVhb) was 
subjected to a further round of infection in HuH-7 cells to generate a working stock. 
 
3.2. Replication kinetics of YFVhb 
To compare the growth of YFVhb with the parent vaccine strain YFV-17D, different 
cell lines were infected at a MOI of 0.01 for 72 hours. After incubation, the culture 
medium was collected, and viral titres were determined by TCID50. YFVhb was 
produced at a considerably lower titre (3 to 4 logs) in Vero and A549 NPro cells than 
the original YFV-17D strain; A549-NPro cells are IRF3 deficient, which can enhance 
the infectivity and replication of various viruses (Hilton et al., 2006). It was 
unexpected to see low titres in Vero and A549- NPro cells, where parental YFV-17D 
can efficiently replicate. In HuH-7 cells both the parental and the reporter virus 
replication reached the same titres after 72 hours. In BHK-21, although replication of 
YFVhb was slightly reduced, the titres were within about 1 log lower of that of YFV-
17D (Fig 2A). To further assess YFVhb replication kinetics, different cell lines were 
infected with the virus at a higher MOI, the accumulation of HiBiT-tagged NS1 was 
monitored over the period of 48 hours (Fig. 2B). Luminescence levels did not 
increase over time in Vero cells, there was a slow increase in case of A549-NPro 
cells, which correlates well with the data shown in Fig. 2A. However, the luciferase 
signal increased steadily in BHK-21 and HuH-7 cells, further suggesting that the 
presence of the tag on NS1 may have cell type specific effects. 
To further correlate YFVhb titres with luciferase signal, HuH-7 cells were infected at 
a MOI of 0.01, and the TCID50 of the released progeny and luciferase were 
measured over a period of seven days. As shown in Fig. 2C, luciferase signal was 
found to be proportional to the viral TCID50 titres, reaching high activities in second 
day of infection and staying till day 5. The highest viral titre was reached at 3 days 
post-infection, however a luciferase signal-to-background ratio of over 1000 was 
observed as early as day 2 post-infection compared to uninfected cells. To design a 
sensitive YFV antiviral assay, cell lines producing the best signal-to-background ratio 
were identified by comparing luminescence between infected and uninfected cell 
lineages (Fig. 2D). Although both HuH-7 and BHK-21 produced a significant signal-
to-background ratio of over 1300 and 50, respectively, HuH-7 provides a wider range 
of luciferase signal. In addition, the signal-to-noise ratio was worst in case of A549-
NPro cells. 
 
3.3. Design of an antiviral screening assay using YFVhb 
To identify the optimal length of infection for the antiviral assay, HuH-7 cells were 
pre-treated with 10 µM MPA, a non-nucleoside inhibitor of inosine monophosphate 
dehydrogenase that has been shown to inhibit a variety of flaviviruses, including YFV 
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(Barrows et al., 2016; Diamond et al., 2002; Neyts et al., 1996; Sebastian et al., 
2011). The IC50 value of MPA has been measured to be 0.25 µM by Neyts et al. 
(1996) in Vero cells, and 0.31 µM by Diamond et al. (2002) in human Hep3B liver 
cells, respectively. After treatment with MPA, cells were washed with PBS, infected 
with YFVhb, and the respective luciferase activity was measured over time. As 
shown in Fig. 3A, at all timepoints, a significantly higher luciferase activity in 
untreated cells compared to treated cells was observed, showing the sensitivity 
range of the assay and indicating the suitability of YFVhb for use in quick drug 
screening assays. Although cells were exposed to an inhibitory MPA concentration, 
YFV is not fully inhibited unless exposed to the drug continuously as previously 
reported (Diamond et al., 2002). Consequently, an increase in the luciferase signal at 
day 3 in MPA-treated cells was observed (Fig. 3A).  
 
3.4. Statistical evaluation of the high throughput assay 
The dynamic range and data variation obtained from the assay was used to 
statistically evaluate the suitability of the assay as a high-throughput assay by 
calculating the Z-factor (Zhang et al., 1999). In addition, the Z-factor may also 
represent an assay validation by measuring the effectiveness of the assay in the 
differentiation of two variables, in this case control-infected and drug-treated 
infection. Overall, the mean luciferase measured in treated cells was >100 times 
lower than untreated cells (Fig. 3B). A Z-factor of 0.69 was calculated, which 
categorises this as an excellent high-throughput screening assay according to Zhang 
et al. (1999). 
 
3.5. Utility of the assay for screening of neutralising antibodies and derivatives  
In addition to rapid drug screening, this assay may be used to characterise 
neutralising antibodies and their derivatives, such as scFvs. Recently, a potently 
neutralising antibody against YFV, named 5A, generated by Daffis et al. (2005), was 
further characterised by Lu et al. (2019). Here we generated the single-chain variant 
fragment scFv-5A to test its neutralization activity in our assay; luciferase activities 
were determined 48 hours post-infection. As shown in Fig. 3C, scFv-5A was able to 
neutralize reporter virus infection in a dose-dependent fashion, exhibiting a 90% 
inhibitory concentration (IC90) value of 0.09 µg/ml. These results are in keeping with 
those reported previously Lu et al. (2019). 
 
3.6. Screening for anti-YFV compounds 
Since MPA is a well-known inhibitor of YFV, we aimed to utilize our reporter virus to 
identify novel antiviral compounds. There are several drugs that are known to inhibit 
other flaviviruses, and to the best of our knowledge have not been yet tested with 
YFV. ARDP0006 (protease inhibitor) has been shown to be antiviral against DENV 
(Tomlinson et al., 2009); another protease inhibitor, Nelfinavir, show activity against 
JEV, ZIKV and WNV (Wang et al., 2017). Sinefungin, a cap-synthesis inhibitor, can 
target WNV (Chen et al., 2013a)  and DENV (Lim et al., 2015). 7DMA, an adenosine 
analogue, has been reported to be antiviral against DENV, ZIKV and TBEV (Eyer et 
al., 2017; Schul et al., 2007; Zmurko et al., 2016). Celgosivir, host alpha-glucosidase 
inhibitor, helps to misfold DENV NS1 protein (Rathore et al., 2011). NS3 helicase 
inhibitor, Ivermectin (Mastrangelo et al., 2012), and nucleoside analogues (MPA and 
Ribavirin) (Diamond et al., 2002; Neyts et al., 1996) were used as positive control, 
and DMSO as a negative control. HuH-7 cells were treated with different drugs 
concentrations 1 hour pre-infection, and thereafter the cells were infected with 
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YFVhb at a MOI of 0.01; the drug was present throughout the course of experiment, 
and in parallel a cytotoxicity assay was conducted (Fig 4A). Of the tested drugs, 
Sinefungin had no effect on YFVhb, whereas 7DMA and Celgosivir showed low 
levels of cytotoxicity and inhibition comparable to MPA and Ribavirin. Nelfinavir 
treatment diminished the luciferase signal, though it was toxic at higher 
concentrations. ARDP0006 was the most toxic of the compounds and its antiviral 
effect is more likely due to cell death, thus, it was omitted from further analysis. To 
confirm that the drugs can target the virus, the most promising compounds were 
tested with YFV-17D at a single non-toxic concentration. We confirmed 7DMA, 
Celgosivir, and Nelfinavir as inhibitors of YFV, as measured by the reduced number 
of released infectious particles from cells (Fig. 4B). 
 
3.8. Utility of the assay for screening sera  
This antiviral test can also be used to determine the generation of protective 
antibodies in sera from immunised animals. We expressed and purified a subunit 
soluble envelope (Fig. 5A) for immunisation and administered to six mice. Three test 
bleeds were carried out and after first and second test bleed the antigen was re-
administrated to boost immunization (Fig. 5B), there was increment of virus E-
specific antibody titres in time as measured by ELISA (Fig. 5C), as expected. A 
curve of inhibition for YFVhb was observed by luciferase measurement; with 2 sera 
out of 6 showing virus neutralization (Fig. 5D). The neutralization capacity of 
antibodies from these two animals was further confirmed by PRNT (Fig. 5E) using 
the parental YFV-17D strain. Overall, our results show that YFVhb can be used in 
quick antiviral screening assays.  
 
4. Discussion 
Here, we used reverse genetic system CPER to generate a HiBiT based reporter 
YFV. The CPER approach has been previously successfully used for ZIKV rescue 
(Setoh et al., 2017) and tagging with HiBiT has been established for other 
flaviviruses (Tamura et al., 2017; Tamura et al., 2019). Reporter viruses containing a 
full reporter protein in the capsid region are often unstable, attenuated, or display 
strong differences in viral growth compared to parental virus (Gadea et al., 2016; 
Schoggins et al., 2012; Vandergaast et al., 2014; Zou et al., 2011). In comparison, 
YFVhb showed no difference in replication to parental YFV-17D in HuH-7 and 
reached comparable titres in BHK-21 cells. Moreover, our data suggest that YFVhb 
can be used to rapidly screen viral inhibitors and may also be used for the study of 
replication, dissemination and potentially tissue tropism in animal models as shown 
by Tamura et al. (2019) for other flaviviruses. We were able to identify three novel 
inhibitors of YFV -7DMA, Celgosivir and Nelfinavir- using our newly developed 
reporter virus. These findings were validated by measuring inhibition of the viral titre 
in parental strain, YFV-17D. 
The current techniques to measure YFV inhibition are often low-throughput, 
unstable, or cannot screen inhibitors against all viral cycle stages. YFVhb described 
here can be used in rapid drug screening and antibody neutralization assays, as 
demonstrated in this study. With all inhibitory compounds, the reporter virus 
displayed a concentration dependent curve of inhibition, which shows the range and 
robustness of the assay. The inhibitory concentrations of MPA, scFv-5A and YFV sE 
immunised mice here reported were comparable to results obtained by other 
classical techniques, which are not amenable for high-throughput assays. Altogether, 
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this assay developed can be a useful tool in the screening of antiviral reagents 
considerably faster than classical techniques.  
In the light of recent major outbreaks in South America, combined with the risk of 
importing the virus into non-endemic areas, YFV has again become a major public 
health concern again (Couto-Lima et al., 2017; Faria et al., 2018; Figueiredo, 2019; 
Jácome et al., 2019; Possas et al., 2018; Vasconcelos and Monath, 2016; Wilder-
Smith, 2019). Although susceptible urbanised areas were identified by the WHO for 
potential YFV outbreaks (E Brent et al., 2018), it is largely envisioned that the current 
vaccine supply would not provide full coverage. There is an urgent need to develop 
treatments against YFV infection. Tools and assays developed over the course of 
this study can support these efforts. A virus with minimum tag or reporter-mediated 
attenuation should greatly facilitate obtaining meaningful data with antivirals or 
antibodies/antibody derivatives. The generation of recombinant flaviviruses involves 
the use of full-length virus cDNA clones, which can be toxic to bacteria during their 
propagation due to leaky expression from cryptic prokaryotic promoters, resulting in 
poor yields (Pu et al., 2011). We would envisage that CPER method can be used to 
insert small tags rapidly into genomes of different (flavi)viruses in multiple locations, 
which permits a faster response in the emergence of epidemics caused by unknown 
RNA viruses to screen for potential antiviral candidates.  
 
Animal work ethical approval 
All animal research described in this study was approved by the University of 
Glasgow Animal Welfare and Ethical Board and was carried out under United 
Kingdom Home Office Licenses, P9722FD8E, in accordance with the approved 
guidelines and under the UK Home Office Animals (Scientific Procedures) Act 1986 
(ASPA). 
 
Acknowledgements 
We thank Professor Thomas Krey (Hannover Medical School), Dr. Hanna Scales 
and professor James Brewer (University of Glasgow), Dr. Oscar Burrone (ICGEB) for 
kindly providing us with reagents. The work described herein was funded by the UK 
Medical Research Council (PhD Studentship to RSV), MC_UU_12014/2 (AHP) and 
MC_UU_12014/8) (AK). The work was also supported in part through National 
Institutes of Health grants R01AI124690 and U19AI057266 (CMR). The content is 
solely the responsibility of the authors and does not necessarily represent the official 
views of the funders. 
 
Author Contribution: 
RSV: Data curation, formal analysis, investigation, methodology, validation, 
visualization, writing-original draft, writing-review and editing. GDL: 
Conceptualization, methodology. RT: Methodology, formal analysis. CS: Validation. 
PJB: Investigation, methodology. LB: Investigation, methodology. MRM: 
Investigation, methodology. JJC: Resources, methodology. CMR: Conceptualization, 
resources, supervision. AP: Funding acquisition, conceptualization, resources, 
project administrator, writing-review and editing. AK: Funding acquisition, 
conceptualization, resources, writing-review and editing. MV: Conceptualization, 
methodology, supervision, writing-original draft, writing-review and editing. 
 
References 
Jo
urn
al 
Pr
e-p
roo
f
  
 
10 
 
Backovic, M., Johansson, D.X., Klupp, B.G., Mettenleiter, T.C., Persson, M.A.A., Rey, F.A., 2010. 
Efficient method for production of high yields of Fab fragments in Drosophila S2 cells. Protein 
Engineering, Design and Selection 23, 169-174. 
Backovic, M., Krey, T., 2016. Stable Drosophila Cell Lines: An Alternative Approach to Exogenous 
Protein Expression. Methods in molecular biology (Clifton, N.J.) 1350, 349-358. 
Barrows, N.J., Campos, R.K., Powell, S.T., Prasanth, K.R., Schott-Lerner, G., Soto-Acosta, R., Galarza-
Munoz, G., McGrath, E.L., Urrabaz-Garza, R., Gao, J., Wu, P., Menon, R., Saade, G., Fernandez-Salas, 
I., Rossi, S.L., Vasilakis, N., Routh, A., Bradrick, S.S., Garcia-Blanco, M.A., 2016. A Screen of FDA-
Approved Drugs for Inhibitors of Zika Virus Infection. Cell host & microbe 20, 259-270. 
Beck, A., Tesh, R.B., Wood, T.G., Widen, S.G., Ryman, K.D., Barrett, A.D., 2014. Comparison of the live 
attenuated yellow fever vaccine 17D-204 strain to its virulent parental strain Asibi by deep 
sequencing. J Infect Dis 209, 334-344. 
Bonaldo, M.C., Mello, S.M., Trindade, G.F., Rangel, A.A., Duarte, A.S., Oliveira, P.J., Freire, M.S., 
Kubelka, C.F., Galler, R., 2007. Construction and characterization of recombinant flaviviruses bearing 
insertions between E and NS1 genes. Virology journal 4, 115. 
Bredenbeek, P.J., Kooi, E.A., Lindenbach, B., Huijkman, N., Rice, C.M., Spaan, W.J., 2003. A stable full-
length yellow fever virus cDNA clone and the role of conserved RNA elements in flavivirus 
replication. The Journal of general virology 84, 1261-1268. 
Chen, H., Liu, L., Jones, S.A., Banavali, N., Kass, J., Li, Z., Zhang, J., Kramer, L.D., Ghosh, A.K., Li, H., 
2013a. Selective inhibition of the West Nile virus methyltransferase by nucleoside analogs. Antiviral 
research 97, 232-239. 
Chen, X., Zaro, J.L., Shen, W.-C., 2013b. Fusion protein linkers: property, design and functionality. 
Adv Drug Deliv Rev 65, 1357-1369. 
Couto-Lima, D., Madec, Y., Bersot, M.I., Campos, S.S., Motta, M.d.A., Santos, F.B.d., Vazeille, M., 
Vasconcelos, P.F.d.C., Lourenço-de-Oliveira, R., Failloux, A.-B., 2017. Potential risk of re-emergence 
of urban transmission of Yellow Fever virus in Brazil facilitated by competent Aedes populations. 
Scientific reports 7, 4848. 
Daffis, S., Kontermann, R.E., Korimbocus, J., Zeller, H., Klenk, H.-D., ter Meulen, J., 2005. Antibody 
responses against wild-type yellow fever virus and the 17D vaccine strain: characterization with 
human monoclonal antibody fragments and neutralization escape variants. Virology 337, 262-272. 
Deng, C.L., Liu, S.Q., Zhou, D.G., Xu, L.L., Li, X.D., Zhang, P.T., Li, P.H., Ye, H.Q., Wei, H.P., Yuan, Z.M., 
Qin, C.F., Zhang, B., 2016. Development of Neutralization Assay Using an eGFP Chikungunya Virus. 
Viruses 8. 
Diamond, M.S., Zachariah, M., Harris, E., 2002. Mycophenolic acid inhibits dengue virus infection by 
preventing replication of viral RNA. Virology 304, 211-221. 
E Brent, S., Watts, A., Cetron, M., German, M., Ug Kraemer, M., Bogoch, I., Brady, O., Hay, S., 
Creatore, M., Khan, K., 2018. International travel between global urban centres vulnerable to yellow 
fever transmission. 
Edmonds, J., van Grinsven, E., Prow, N., Bosco-Lauth, A., Brault, A., Bowen, R., A Hall, R., Khromykh, 
A., 2012. A Novel Bacterium-Free Method for Generation of Flavivirus Infectious DNA by Circular 
Polymerase Extension Reaction Allows Accurate Recapitulation of Viral Heterogeneity. Journal of 
virology 87. 
Eyer, L., Kondo, H., Zouharova, D., Hirano, M., Valdés, J.J., Muto, M., Kastl, T., Kobayashi, S., 
Haviernik, J., Igarashi, M., Kariwa, H., Vaculovicova, M., Cerny, J., Kizek, R., Kröger, A., Lienenklaus, S., 
Dejmek, M., Nencka, R., Palus, M., Salat, J., De Clercq, E., Yoshii, K., Ruzek, D., 2017. Escape of Tick-
Borne Flavivirus from 2′-C-Methylated Nucleoside Antivirals Is Mediated by a Single Conservative 
Mutation in NS5 That Has a Dramatic Effect on Viral Fitness.  91, e01028-01017. 
Eyre, N.S., Johnson, S.M., Eltahla, A.A., Aloi, M., Aloia, A.L., McDevitt, C.A., Bull, R.A., Beard, M.R., 
2017. Genome-Wide Mutagenesis of Dengue Virus Reveals Plasticity of the NS1 Protein and Enables 
Generation of Infectious Tagged Reporter Viruses. Journal of Virology 91, e01455-01417. 
Jo
urn
al 
Pr
e-p
roo
f
  
 
11 
 
Faria, N.R., Kraemer, M.U.G., Hill, S.C., Goes de Jesus, J., Aguiar, R.S., Iani, F.C.M., Xavier, J., Quick, J., 
du Plessis, L., Dellicour, S., Theze, J., Carvalho, R.D.O., Baele, G., Wu, C.H., Silveira, P.P., Arruda, M.B., 
Pereira, M.A., Pereira, G.C., Lourenco, J., Obolski, U., Abade, L., Vasylyeva, T.I., Giovanetti, M., Yi, D., 
Weiss, D.J., Wint, G.R.W., Shearer, F.M., Funk, S., Nikolay, B., Fonseca, V., Adelino, T.E.R., Oliveira, 
M.A.A., Silva, M.V.F., Sacchetto, L., Figueiredo, P.O., Rezende, I.M., Mello, E.M., Said, R.F.C., Santos, 
D.A., Ferraz, M.L., Brito, M.G., Santana, L.F., Menezes, M.T., Brindeiro, R.M., Tanuri, A., Dos Santos, 
F.C.P., Cunha, M.S., Nogueira, J.S., Rocco, I.M., da Costa, A.C., Komninakis, S.C.V., Azevedo, V., 
Chieppe, A.O., Araujo, E.S.M., Mendonca, M.C.L., Dos Santos, C.C., Dos Santos, C.D., Mares-Guia, 
A.M., Nogueira, R.M.R., Sequeira, P.C., Abreu, R.G., Garcia, M.H.O., Abreu, A.L., Okumoto, O., Kroon, 
E.G., de Albuquerque, C.F.C., Lewandowski, K., Pullan, S.T., Carroll, M., de Oliveira, T., Sabino, E.C., 
Souza, R.P., Suchard, M.A., Lemey, P., Trindade, G.S., Drumond, B.P., Filippis, A.M.B., Loman, N.J., 
Cauchemez, S., Alcantara, L.C.J., Pybus, O.G., 2018. Genomic and epidemiological monitoring of 
yellow fever virus transmission potential. Science (New York, N.Y.) 361, 894-899. 
Figueiredo, L.T.M., 2019. Human Urban Arboviruses Can Infect Wild Animals and Jump to Sylvatic 
Maintenance Cycles in South America. Frontiers in cellular and infection microbiology 9, 259. 
Gadea, G., Bos, S., Krejbich-Trotot, P., Clain, E., Viranaicken, W., El-Kalamouni, C., Mavingui, P., 
Despres, P., 2016. A robust method for the rapid generation of recombinant Zika virus expressing the 
GFP reporter gene. Virology 497, 157-162. 
Goldani, L.Z., 2017. Yellow fever outbreak in Brazil, 2017. The Brazilian journal of infectious diseases 
: an official publication of the Brazilian Society of Infectious Diseases 21, 123-124. 
Henchal, E.A., Gentry, M.K., McCown, J.M., Brandt, W.E., 1982. Dengue virus-specific and flavivirus 
group determinants identified with monoclonal antibodies by indirect immunofluorescence. The 
American journal of tropical medicine and hygiene 31, 830-836. 
Hierholzer, J., Killington, R., 1996. Virus isolation and quantitation, Virology methods manual. 
Elsevier, pp. 25-46. 
Hilton, L., Moganeradj, K., Zhang, G., Chen, Y.H., Randall, R.E., McCauley, J.W., Goodbourn, S., 2006. 
The NPro product of bovine viral diarrhea virus inhibits DNA binding by interferon regulatory factor 3 
and targets it for proteasomal degradation. J Virol 80, 11723-11732. 
Huang, Y.-M., 1986. Aedes (Stegomyia) Bromeliae (Diptera: Culicidae), the Yellow Fever Virus Vector 
in East Africa1. Journal of Medical Entomology 23, 196-200. 
Jácome, R., Carrasco-Hernández, R., Campillo-Balderas, J.A., López-Vidal, Y., Lazcano, A., Wenzel, 
R.P., Ponce de León, S., 2019. A yellow flag on the horizon: The looming threat of yellow fever to 
North America. International Journal of Infectious Diseases 87, 143-150. 
Jones, C.T., Patkar, C.G., Kuhn, R.J., 2005. Construction and applications of yellow fever virus 
replicons. Virology 331, 247-259. 
Julander, J.G., Testori, M., Cheminay, C., Volkmann, A., 2018. Immunogenicity and Protection After 
Vaccination With a Modified Vaccinia Virus Ankara-Vectored Yellow Fever Vaccine in the Hamster 
Model. Frontiers in immunology 9, 1756. 
Kassar, T.C., Magalhaes, T., Junior, S.J., Carvalho, A.G.O., Silva, A., Queiroz, S.R.A., Bertani, G.R., Gil, 
L., 2017. Construction and characterization of a recombinant yellow fever virus stably expressing 
Gaussia luciferase. Anais da Academia Brasileira de Ciencias 89, 2119-2130. 
Lim, S.P., Noble, C.G., Shi, P.Y., 2015. The dengue virus NS5 protein as a target for drug discovery. 
Antiviral research 119, 57-67. 
Lu, X., Xiao, H., Li, S., Pang, X., Song, J., Liu, S., Cheng, H., Li, Y., Wang, X., Huang, C., Guo, T., Ter 
Meulen, J., Daffis, S., Yan, J., Dai, L., Rao, Z., Klenk, H.D., Qi, J., Shi, Y., Gao, G.F., 2019. Double Lock of 
a Human Neutralizing and Protective Monoclonal Antibody Targeting the Yellow Fever Virus 
Envelope. Cell reports 26, 438-446.e435. 
Mastrangelo, E., Pezzullo, M., De Burghgraeve, T., Kaptein, S., Pastorino, B., Dallmeier, K., de 
Lamballerie, X., Neyts, J., Hanson, A.M., Frick, D.N., Bolognesi, M., Milani, M., 2012. Ivermectin is a 
potent inhibitor of flavivirus replication specifically targeting NS3 helicase activity: new prospects for 
an old drug. J Antimicrob Chemother 67, 1884-1894. 
Jo
urn
al 
Pr
e-p
roo
f
  
 
12 
 
Mayhoub, A.S., Khaliq, M., Kuhn, R.J., Cushman, M., 2011. Design, synthesis, and biological 
evaluation of thiazoles targeting flavivirus envelope proteins. Journal of medicinal chemistry 54, 
1704-1714. 
Monath, T.P., 1994. Yellow fever and dengue—the interactions of virus, vector and host in the re-
emergence of epidemic disease. Seminars in Virology 5, 133-145. 
Monath, T.P., 2008. Treatment of yellow fever. Antiviral research 78, 116-124. 
Monath, T.P., Lee, C.K., Julander, J.G., Brown, A., Beasley, D.W., Watts, D.M., Hayman, E., Guertin, P., 
Makowiecki, J., Crowell, J., Levesque, P., Bowick, G.C., Morin, M., Fowler, E., Trent, D.W., 2010. 
Inactivated yellow fever 17D vaccine: development and nonclinical safety, immunogenicity and 
protective activity. Vaccine 28, 3827-3840. 
Mutebi, J.P., Barrett, A.D., 2002. The epidemiology of yellow fever in Africa. Microbes and infection 
4, 1459-1468. 
Neyts, J., Meerbach, A., McKenna, P., De Clercq, E., 1996. Use of the yellow fever virus vaccine strain 
17D for the study of strategies for the treatment of yellow fever virus infections. Antiviral research 
30, 125-132. 
Otshudiema, J., Ndakala, N., Mawanda Kimvuidi, E.-T., Tshapenda, G., Kimfuta, J., Nsibu, L.-R., 
Gueye, A.S., Dee, J., Philen, R., Giese, C., Murrill, C., Arthur, R., Kebela, B., 2017. Yellow Fever 
Outbreak — Kongo Central Province, Democratic Republic of the Congo, August 2016. MMWR. 
Morbidity and mortality weekly report 66, 335-338. 
Patkar, C.G., Larsen, M., Owston, M., Smith, J.L., Kuhn, R.J., 2009. Identification of inhibitors of 
yellow fever virus replication using a replicon-based high-throughput assay. Antimicrobial agents and 
chemotherapy 53, 4103-4114. 
Pato, T.P., Souza, M.C.O., Mattos, D.A., Caride, E., Ferreira, D.F., Gaspar, L.P., Freire, M.S., Castilho, 
L.R., 2019. Purification of yellow fever virus produced in Vero cells for inactivated vaccine 
manufacture. Vaccine 37, 3214-3220. 
Possas, C., Lourenço-de-Oliveira, R., Tauil, P.L., Pinheiro, F.d.P., Pissinatti, A., Cunha, R.V.d., Freire, 
M., Martins, R.M., Homma, A., 2018. Yellow fever outbreak in Brazil: the puzzle of rapid viral spread 
and challenges for immunisation. Memorias do Instituto Oswaldo Cruz 113. 
Pu, S.Y., Wu, R.H., Yang, C.C., Jao, T.M., Tsai, M.H., Wang, J.C., Lin, H.M., Chao, Y.S., Yueh, A., 2011. 
Successful propagation of flavivirus infectious cDNAs by a novel method to reduce the cryptic 
bacterial promoter activity of virus genomes. J Virol 85, 2927-2941. 
Queiroz, S.R., Silva, A.N., Santos, J.J., Marques, E.T., Jr., Bertani, G.R., Gil, L.H., 2013. Construction of 
yellow fever virus subgenomic replicons by yeast-based homologous recombination cloning 
technique. Anais da Academia Brasileira de Ciencias 85, 159-168. 
Rathore, A.P., Paradkar, P.N., Watanabe, S., Tan, K.H., Sung, C., Connolly, J.E., Low, J., Ooi, E.E., 
Vasudevan, S.G., 2011. Celgosivir treatment misfolds dengue virus NS1 protein, induces cellular pro-
survival genes and protects against lethal challenge mouse model. Antiviral research 92, 453-460. 
Schoggins, J.W., Dorner, M., Feulner, M., Imanaka, N., Murphy, M.Y., Ploss, A., Rice, C.M., 2012. 
Dengue reporter viruses reveal viral dynamics in interferon receptor-deficient mice and sensitivity to 
interferon effectors in vitro. Proceedings of the National Academy of Sciences of the United States of 
America 109, 14610-14615. 
Schul, W., Liu, W., Xu, H.Y., Flamand, M., Vasudevan, S.G., 2007. A dengue fever viremia model in 
mice shows reduction in viral replication and suppression of the inflammatory response after 
treatment with antiviral drugs. J Infect Dis 195, 665-674. 
Schwinn, M.K., Machleidt, T., Zimmerman, K., Eggers, C.T., Dixon, A.S., Hurst, R., Hall, M.P., Encell, 
L.P., Binkowski, B.F., Wood, K.V., 2018. CRISPR-Mediated Tagging of Endogenous Proteins with a 
Luminescent Peptide. ACS Chemical Biology 13, 467-474. 
Sebastian, L., Madhusudana, S.N., Ravi, V., Desai, A., 2011. Mycophenolic Acid Inhibits Replication of 
Japanese Encephalitis Virus. Chemotherapy 57, 56-61. 
J
urn
l P
re-
pro
of
  
 
13 
 
Setoh, Y.X., Prow, N.A., Peng, N., Hugo, L.E., Devine, G., Hazlewood, J.E., Suhrbier, A., Khromykh, 
A.A., 2017. De Novo Generation and Characterization of New Zika Virus Isolate Using Sequence Data 
from a Microcephaly Case. mSphere 2, e00190-00117. 
Song, K.Y., Zhao, H., Jiang, Z.Y., Li, X.F., Deng, Y.Q., Jiang, T., Zhu, S.Y., Shi, P.Y., Zhang, B., Zhang, F.C., 
Qin, E.D., Qin, C.F., 2014. A novel reporter system for neutralizing and enhancing antibody assay 
against dengue virus. BMC microbiology 14, 44. 
Spector, S., Tauraso, N.M., 1968. Yellow Fever Virus. I. Development and Evaluation of a Plaque 
Neutralization Test 16, 1770-1775. 
Tamura, T., Fukuhara, T., Uchida, T., Ono, C., Mori, H., Sato, A., Fauzyah, Y., Okamoto, T., Kurosu, T., 
Setoh, Y.X., Imamura, M., Tautz, N., Sakoda, Y., Khromykh, A.A., Chayama, K., Matsuura, Y., 2017. 
Characterization of recombinantFlaviviridaeviruses possessing a small reporter-tag. Journal of 
Virology, JVI.01582-01517. 
Tamura, T., Igarashi, M., Enkhbold, B., Suzuki, T., Okamatsu, M., Ono, C., Mori, H., Izumi, T., Sato, A., 
Fauzyah, Y., Okamoto, T., Sakoda, Y., Fukuhara, T., Matsuura, Y., 2019. In Vivo Dynamics of Reporter 
Flaviviridae Viruses. Journal of Virology 93, e01191-01119. 
Theiler, M., Smith, H.H., 1937. THE USE OF YELLOW FEVER VIRUS MODIFIED BY IN VITRO 
CULTIVATION FOR HUMAN IMMUNIZATION. J Exp Med 65, 787-800. 
Tomlinson, S.M., Malmstrom, R.D., Russo, A., Mueller, N., Pang, Y.-P., Watowich, S.J., 2009. 
Structure-based discovery of dengue virus protease inhibitors. Antiviral research 82, 110-114. 
Tottey, S., Shoji, Y., Jones, R.M., Chichester, J.A., Green, B.J., Musiychuk, K., Si, H., Manceva, S.D., 
Rhee, A., Shamloul, M., Norikane, J., Guimaraes, R.C., Caride, E., Silva, A., Simoes, M., Neves, P.C.C., 
Marchevsky, R., Freire, M.S., Streatfield, S.J., Yusibov, V., 2018. Plant-Produced Subunit Vaccine 
Candidates against Yellow Fever Induce Virus Neutralizing Antibodies and Confer Protection against 
Viral Challenge in Animal Models. The American journal of tropical medicine and hygiene 98, 420-
431. 
Vandergaast, R., Hoover, L.I., Zheng, K., Fredericksen, B.L., 2014. Generation of West Nile virus 
infectious clones containing amino acid insertions between capsid and capsid anchor. Viruses 6, 
1637-1653. 
Vasconcelos, P.F., Monath, T.P., 2016. Yellow Fever Remains a Potential Threat to Public Health. 
Vector borne and zoonotic diseases (Larchmont, N.Y.) 16, 566-567. 
Vasconcelos, P.F.C., Sperb, A.F., Monteiro, H.A.O., Torres, M.A.N., Sousa, M.R.S., Vasconcelos, H.B., 
Mardini, L.B.L.F., Rodrigues, S.G., 2003. Isolations of yellow fever virus from Haemagogus 
leucocelaenus in Rio Grande do Sul State, Brazil. Transactions of the Royal Society of Tropical 
Medicine and Hygiene 97, 60-62. 
Vratskikh, O., Stiasny, K., Zlatkovic, J., Tsouchnikas, G., Jarmer, J., Karrer, U., Roggendorf, M., 
Roggendorf, H., Allwinn, R., Heinz, F.X., 2013. Dissection of antibody specificities induced by yellow 
fever vaccination. PLoS pathogens 9, e1003458. 
Wang, S., Liu, Y., Guo, J., Wang, P., Zhang, L., Xiao, G., Wang, W., 2017. Screening of FDA-Approved 
Drugs for Inhibitors of Japanese Encephalitis Virus Infection.  91, e01055-01017. 
Wilder-Smith, A., 2019. Yellow Fever in Travelers. Current infectious disease reports 21, 42. 
Zhang, J.H., Chung, T.D., Oldenburg, K.R., 1999. A Simple Statistical Parameter for Use in Evaluation 
and Validation of High Throughput Screening Assays. Journal of biomolecular screening 4, 67-73. 
Zhang, P.T., Shan, C., Li, X.D., Liu, S.Q., Deng, C.L., Ye, H.Q., Shang, B.D., Shi, P.Y., Lv, M., Shen, B.F., 
Qin, C.F., Zhang, B., 2016. Generation of a recombinant West Nile virus stably expressing the Gaussia 
luciferase for neutralization assay. Virus research 211, 17-24. 
Zmurko, J., Marques, R.E., Schols, D., Verbeken, E., Kaptein, S.J., Neyts, J., 2016. The Viral Polymerase 
Inhibitor 7-Deaza-2'-C-Methyladenosine Is a Potent Inhibitor of In Vitro Zika Virus Replication and 
Delays Disease Progression in a Robust Mouse Infection Model. PLoS neglected tropical diseases 10, 
e0004695. 
Zou, G., Xu, H.Y., Qing, M., Wang, Q.Y., Shi, P.Y., 2011. Development and characterization of a stable 
luciferase dengue virus for high-throughput screening. Antiviral research 91, 11-19. 
Jo
urn
al 
Pr
e-p
roo
f
  
 
14 
 
 
 
 
FIGURE LEGENDS 
Figure 1. Addition of a small tag to YFV NS1. (A) An eleven amino acid reporter 
tag was placed at the N terminus of the NS1 protein. The reporter fragment 
consisted of the initial four amino acids of NS1 (DQGC) encoded by different codons 
to the original sequence, followed by the HiBiT tag (VSGWRLFKKIS), and a 4GS 
linker (GSSG). (B) The YFV genomic clone was used to amplify 7 fragments, F1-F7, 
an additional fragment containing the HiBiT reporter tag (*), was also included. 
These 8 overlapping fragments were mixed in equimolar concentrations with a linker 
containing a CMV promoter at the 5’ end, a HDVr, and a pA at the 3’ end. The 
fragments were subjected to CPER to generate circular genomes, which were 
transfected to BHK-21 cells to produce the reporter virus. 
 
Figure 2. Comparative growth of YFVhb and YFV-17D. (A) The indicated cell lines 
were infected with either YFV-17D or YFVhb at MOI 0.01, at 72 hours post infection, 
supernatant containing virus progeny was titrated by TCID50; error bars depict the 
standard error of the mean (SEM) of three independent titrations. (B) Vero, BHK-21, 
HuH-7, and A549-NPro were infected with YFVhb at a MOI of 1 to investigate the 
replication kinetics of YFVhb. Viral replication was assessed at different time points 
by measuring the luminescence. Error bars represent SEM from three independent 
experiments performed in duplicate. (C) HuH-7 cells infected with YFVhb at a MOI of 
0.01 were monitored daily for TCID50 and luciferase signal; error bars depict the SEM 
of the luciferase activity of three independent experiments conducted in triplicate; 
titration of virus was done in singlicate in three independent experiments. (D) Cells 
were infected with YFVhb at MOI 0.01 or mock-infected with PBS. After 72 hours, 
the luciferase activity was measured. Error bars depict the SEM of the luciferase 
activity of three independent experiments performed in triplicate.  
 
Figure 3. Testing suitability of YFVhb for screening of antiviral compounds. (A) 
HuH-7 cells were either pre-treated with MPA at 10 µM or left untreated for 1 hour, 
cells were then washed and infected with YFVhb, as a negative control, a group of 
cells were left uninfected to monitor background signal caused by uninfected cells; 
luciferase activity was measured daily over a period of three days post infection, 
error bars depict the SEM of the luciferase signal from three independent 
experiments in duplicate. Statistical significance was determined using T-test without 
correction for multiple comparisons, with alpha=0.05, without assuming a consistent 
SD using GraphPad Prism (** P ≤0.01; *** P ≤0.001). (B) To calculate the Z-factor of 
the assay, 40 replicates were either treated with 10 µM MPA or MPA vehicle 
(methanol) and infected with YFVhb. The established parameters of the assay were 
used, and luciferase was measured 48 hours post-infection. (C) 400 virus infectious 
units were incubated with 10-fold serial dilutions of the scFv-5A. Then, the mixture of 
virus with scFv-5A was used to infect HuH-7 cells for 48 hours. A group of cells were 
treated with an equal volume of scFv vehicle, PBS, before infection and luciferase 
values were set as 100% infection. Error bars represent SEM of three independent 
experiments conducted in triplicate. 
 
Figure 4. Inhibition of YFVhb by a panel of drugs. (A) HuH-7 cells were pre-
treated with serial three-fold dilutions of a panel of drugs or their vehicle (DMSO). 
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Cells were infected with YFVhb as described in Methods. Luciferase readings were 
normalised to vehicle values, set to 100%. Cell viability was measured with WST-1 
reagent (Roche) in a colorimetric assay, and the readings were normalised to vehicle 
values set at 100% cell viability. Error bars represent SEM of triplicates in three 
independent experiments. (B) The inhibitory activity of the panel of drugs was tested 
using the parental YFV-17D by measuring the reduction of viral titres compared to 
the drug vehicle. Error bars represent the SEM of three independent biological 
experiments.  
Figure 5. Inhibition of YFV replication by antibodies from sE-immunised mice. 
(A) YFV soluble envelope protein was transfected into Expi293F cells for 5 days. 
The protein was purified by affinity chromatography. Samples from each step of the 
purification were separated by SDS-PAGE and analysed by Western blot using a 
monoclonal anti-V5 tag antibody; 0- molecular weight, 1- cell extract from transfected 
cells, 2- supernatant from transfected cells, 3- purification flow through, 4-12 
fractions eluted from ÄKTA Pure (GE Healthcare) system. (B) Mice (n=6) were 
immunised with 5 µg of purified YFV soluble E protein. Test bleeds (TB) were taken 
2-3 weeks after each immunisation/boost. (C) Dilutions of test bleeds obtained 
throughout the course of the immunisation were tested in an ELISA format for 
recognition of YFV E. The anti-YFV E titre of each test bleed was defined as the 
reciprocal of the last dilution which generated a colorimetric signal at least three 
times higher than normal mouse sera (NMS). (D) Dilutions of the sera obtained from 
mice immunised with YFV sE were mixed with 400 YFVhb infectious units for 1 hour 
before infecting HuH-7 cells. Luciferase activities were determined at 48 hours post-
infection; error bars represent SEM of three independent experiments done in 
singlicate. Luciferase produced by NMS was considered 100% infection.  (E) 
Dilutions of the sera obtained from mice immunised with sE were mixed with 80 
YFV-17D infectious units for 1 hour before infecting Vero cells and application of a 
semi-solid overlay; cells were incubated for 6-7 days and stained with 0.1% crystal 
violet. The PRNTs were performed three times in singlicate for each serum dilution. 
 
SUPPLEMENTARY DATA 
Supplementary Table S1. Primers used to amplify YFV genome overlapping 
fragments for CPER. 
Supplementary Sequence S1. Binding sites of primers in plasmid pACNR-
2015FLYF-17Da. The primer binding sites are show in bold typeface. 
Supplementary Sequence S2. Fragment containing HiBiT tag. The fragment 
containing the HiBiT tag was synthesised. Primer binding sites used to amplify this 
region is underlined. Fragment containing the first 4 amino acids of NS1-HiBiT tag 
and GSSG linker is in bold letters. 
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Highlights 
• Bacteria-free approach to rescue yellow fever virus 
• Novel tagged yellow fever virus that permits quantifiable assays 
• Usage of the novel tagged virus for screening of antivirals and immune sera 
• Novel antiviral compounds against YFV were identified 
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